Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Southern is an Associate Staff Physician at the Respiratory Institute and holds a secondary appointment in the Lerner Research Institute Department of Pathobiology, where his research focus is Idiopathic Pulmonary Fibrosis (IPF). In the laboratory of Dr. Mitchell Olman, Dr. Southern helped develop a novel tissue-based assay to explore how fibroblasts and myofibroblasts (the scar-producing cells in IPF) interact with lung tissue matrix to propagate fibrosis. Using this method he has identified that, through activation of a motor protein called myosin II, normal lung tissue signals fibroblasts to migrate, while fibrotic lung tissue induces myofibroblast differentiation. His current research involves further exploration of the myosin II pathway to identify novel targets to stop the fibrotic process in patients with IPF. In addition, Dr. Southern conducts an outpatient clinic where he treats patients with all forms of interstitial lung disease and sarcoidosis. He serves as a co-investigator on a number of clinical trials for patients with IPF. He also supervises trainees in the Pulmonary Fellow Interstitial Lung Disease Clinic and on the inpatient pulmonary consult service.
Since joining the staff of the Cleveland Clinic in 2012, Dr.Southern has been invited to present his research findings at the American Thoracic Society International Conference, the Keystone Symposium on Fibrosis,and The Society for Clinical Research/Midwestern Section American Federation for Medical Research (CSCR/MWAFMR). He has received a funding award from the Research Program Committee at the Cleveland Clinic. He has served on the Intermune Advisory Board, and reviews manuscripts for the American Journal of Respiratory and Critical Care Medicine and the Journal of Biological Chemistry. Additionally, he serves as a volunteer physician at the Free Clinic and with MedWorks USA in Cleveland, OH.
Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases, Sarcoidosis
American Thoracic Society, American Society for Matrix Biology, American Association for the Advancement of Science
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 3/7/2014, Dr. Southern has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.